Published in:
08-02-2023 | Esophageal Cancer | Original Article
Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma
Authors:
Takumi Habu, Ryosuke Kumanishi, Takatsugu Ogata, Takeshi Fujisawa, Saori Mishima, Daisuke Kotani, Shigenori Kadowaki, Masaki Nakamura, Hidehiro Hojo, Hisashi Fujiwara, Shogo Kumagai, Shohei Koyama, Takeo Fujita, Takahiro Kinoshita, Hiroyoshi Nishikawa, Tomonori Yano, Masahiro Tajika, Kei Muro, Shuichi Mitsunaga, Takashi Kojima, Hideaki Bando
Published in:
Esophagus
|
Issue 3/2023
Login to get access
Abstract
Background
Although definitive chemoradiotherapy (CRT) is the standard therapy for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC), poor survival has been reported. Although the complete response (CR) rate is strongly correlated with good prognosis, the predictive factors for CR have not been elucidated.
Methods
This registry study aimed to identify predictors of CR to definitive CRT in patients with unresectable locally advanced ESCC. “Unresectable” was defined as the primary lesion invading unresectable adjacent structures such as the aorta, vertebral body, and trachea (T4b), or the regional and/or supraclavicular lymph nodes invading unresectable adjacent structures (LNT4b).
Results
Overall, 175 patients who started definitive CRT between January 2013 and March 2020 were included. The confirmed CR (cCR) rate was 24% (42/175). The 2-year progression-free survival (PFS) and overall survival (OS) rates of cCR cases vs. non-cCR cases were 59% vs. 2% (log-rank p < 0.001) and 90% vs. 31% (log-rank p < 0.001), with a median follow-up period of 18.5 and 40.5 months, respectively. Multivariate analysis of clinicopathological factors revealed that tumor length ≥ 6 cm [odds ratio (OR) 0.446; 95% CI 0.220–0.905; p = 0.025] was a predictor of cCR.
Conclusions
Favorable PFS and OS rates were observed in patients with cCR. Tumor length was a predictive factor for cCR.